Please login to the form below

Not currently logged in
Email:
Password:

Beijing Med-Pharm signs ondansetron agreement with Shanghai Ethypharm

Beijing Med-Pharm has signed an exclusive license agreement with Shanghai Ethypharm Pharmaceutical, a subsidiary of the French drug delivery company Ethypharm, where Beijing Med-Pharm will market and distribute ondansetron Flashtab (4 and 8 mg) in the People's Republic of China.

Beijing Med-Pharm has signed an exclusive license agreement with Shanghai Ethypharm Pharmaceutical, a subsidiary of the French drug delivery company Ethypharm, where Beijing Med-Pharm will market and distribute ondansetron Flashtab (4 and 8 mg) in the People's Republic of China.

Under the terms of the agreement, Shanghai Ethypharm will pursue registration of ondansetron Flashtabin China, a process expected to be completed in 2009. Beijing Med-Pharm will take on responsibility for sales, marketing, distribution and supply.

David Gao, CEO of Beijing Med-Pharm, said: "Ondansetron is a significant global product that complements our plans in oncology and the portfolio of supportive therapies we are building for that market, including Galake, the analgesic we recently licensed from Lotus. We are very pleased to be entering our first collaboration with one of Europe's leading drug delivery companies."

"Ethypharm has made a significant corporate commitment to entering Asian markets and we believe there is a substantial opportunity in China for our Flashtab ondansetron product," said Philippe Malecki, General Manager of Shanghai Ethypharm. "Offering comprehensive sales and marketing support as well as a proprietary distribution system reaching major Chinese markets, we believe Beijing Med-Pharm represents a unique resource for expediting the successful launch of this product and generating rapid sales growth."

Ondansetron is the generic form of Zofran, the world leader in the 5-HT(3) antagonist class of antiemetics. Ondansetron reduces nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy and to prevent post-operative nausea and vomiting.

Ethypharm manufactures the product using its proprietary Flashtab orally disintegrating tablet technology.

 

25th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...